Journal profile · Urology & Nephrology
Clinical Genitourinary Cancer
ISSN 1558-7673 · eISSN 1938-0682 · Elsevier · UNITED STATES · Quarterly · Founded 2005
Clinical Genitourinary Cancer: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.44; hybrid open access; APC about USD 3,530; median 72 days to acceptance (112 articles, last 24 months); community-reported acceptance: easy; 194 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Clinical Genitourinary Cancer is published by Elsevier and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Bladder and Urothelial Cancer Treatments, Renal cell carcinoma treatment and Prostate Cancer Treatment and Research, together about 43.1% of its articles. Its main subfields are Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches. Priority is given to studies using authors' own institutional or original patient cohorts. Secondary analyses of public registries or databases (e.g., SEER, TCGA) are discouraged unless they generate genuinely novel clinical or mechanistic insight not already addressable with the same data.
From the journal's Aims & Scope
Research area (LetPub): Urology & Nephrology
Editor-in-chief Leonard ApplemanPublisher website
Editorial board by country: 5 in mainland China (about 9%); most named United States 37, Italy 8, Mainland China 5, United Kingdom 2, Spain 1 (58 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Bladder and Urothelial Cancer TreatmentsMedicine14.8%
- Renal cell carcinoma treatmentMedicine14.4%
- Prostate Cancer Treatment and ResearchMedicine13.8%
- Prostate Cancer Diagnosis and TreatmentMedicine12%
- Urinary and Genital Oncology StudiesMedicine6.5%
- Cancer Immunotherapy and BiomarkersMedicine3.7%
- Multiple and Secondary Primary CancersMedicine3.1%
- Renal and related cancersBiochemistry, Genetics and Molecular Biology3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Urology & Nephrology | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Urology & Nephrology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Urology & Nephrology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.44LetPub ·
- Impact factor (publisher)
- 2.4Publisher website ·
- CiteScore 2026-06
- 4LetPub ·
- CiteScore (publisher)
- 4Publisher website ·
- SJR 2026-06
- 1.05LetPub ·
- SNIP 2026-06
- 0.8LetPub ·
- h-index
- 40LetPub ·
- h-index
- 69OpenAlex ·
- i10-index
- 1,347OpenAlex ·
- 2-year mean citedness
- 2.53OpenAlex ·
- Self-citation rate
- 4.2%LetPub ·
- Share of gold OA articles
- 19.53%LetPub ·
Volume
- Articles per year
- 172LetPub ·
Articles by year OpenAlex count · 3,010 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 177 | 56 | 42 |
| 2025 | 194 | 81 | 393 |
| 2024 | 269 | 107 | 1,182 |
| 2023 | 175 | 80 | 1,406 |
| 2022 | 180 | 76 | 1,535 |
| 2021 | 150 | 64 | 1,899 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
72 daysMedian, submission to acceptance · P25–P75 49 days – 100 days
- Acceptance to online
- median 5 days (112 articles)
- Submission to online
- median 80 days
- Sample
- 112 articles with submission and acceptance dates (475 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Submission to first decision
- 8 daysPublisher website ·
- First decision after review
- 41 daysPublisher website ·
- Submission to acceptance
- 78 daysPublisher website ·
- Acceptance to publication
- 4 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,530 / EUR 3,300 / GBP 2,830 / JPY 437,830 | — | — | |
| Publisher website | USD 3,770 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare6 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Manuscript length
- ≤ 8,000 words
- Reference style
- Numbered, in order of citation
- Highlights
- Optional
- Graphical abstract
- Optional
Article types accepted8, with length limits
- case reportFor case reports you are required to follow CARE guidelines and provide the CARE checklist at manuscript submission.Read the CARE guidelinesFollow the CARE chec…Length not stated
- commentaryCommentary: Commentary articles present original perspectives on novel or controversial clinical topics that warrant rapid dissemination.Length not stated
- editorialef prior to submission. Article Format: Editorials contain approximately 1,000 - 2,000 words, and no abstract. Peer review This journal follows a singlemain text ≤ 2,000 words
- original studyOriginal Study: Original Study articles present results of original clinical research and/or translational research with clear clinical implications.Length not stated
- perspectivePerspective: Perspective articles provide focused discussions of important clinical topics from a specific viewpoint or opinion.Length not stated
- reviewOriginal Study: Original Study articles present results of original clinical research and/or translational research with clear clinical implications. These arti…Length not stated
- review articleOriginal Study: Original Study articles present results of original clinical research and/or translational research with clear clinical implications. These arti…Length not stated
- systematic reviewSystematic Review: Systematic Review articles rigorously collect, evaluate, and synthesize data from multiple studies to provide evidence-based conclusions on c…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Publication ethics
Publishing ethics policy Model summary
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Quarterly
- Founded
- 2005
- ISSN
- 1558-7673
- Electronic ISSN
- 1938-0682
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Clinical Genitourinary Cancer
What CAS zone is Clinical Genitourinary Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical Genitourinary Cancer is in Zone 3 of Medicine, and in Zone 3 of the minor category Urology & Nephrology / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical Genitourinary Cancer?
The latest impact factor listed by LetPub is 2.44; CiteScore 4, h-index 69.
How long does peer review take at Clinical Genitourinary Cancer?
Based on the dates recorded on 112 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 72 days (interquartile range 49–100 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Clinical Genitourinary Cancer?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Manuscript length: ≤ 8,000 words; Reference style: Numbered, in order of citation; Highlights: Optional; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Clinical Genitourinary Cancer based?
Of the 58 board members whose country the journal's board page names, 5 (about 9%) are in mainland China; the countries named most often are United States (37), Italy (8) and Mainland China (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Clinical Genitourinary Cancer?
According to LetPub and DOAJ records, Clinical Genitourinary Cancer is indexed in SCIE and Scopus.
Is Clinical Genitourinary Cancer open access, and what is the APC?
Clinical Genitourinary Cancer is a hybrid journal. For open-access publication: APC about USD 3,530.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .